Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Dharam J. Kumbhani et al. published in JACC Journals, adding:
“Antiplatelet Therapy in Atherosclerotic Cardiovascular Disease: Toward a Personalized Strategy
The 2026 American College of Cardiology (ACC) Scientific Statement represents one of the most comprehensive updates on antiplatelet therapy in patients with atherosclerotic cardiovascular disease (ASCVD).
Rather than introducing a single new treatment paradigm, the document emphasizes individualized decision-making, recognizing that optimal therapy depends on balancing each patient’s ischemic and bleeding risks.
One of the statement’s most important messages is that routine aspirin for primary prevention is no longer appropriate for most individuals.
Contemporary preventive strategies—including intensive lipid lowering, blood pressure control, smoking cessation, and diabetes management—have substantially reduced aspirin’s incremental benefit while its bleeding risk remains unchanged.
Consequently, low-dose aspirin should be reserved for carefully selected adults aged 40–70 years with elevated cardiovascular risk and low bleeding risk, whereas routine use in adults older than 70 years is generally discouraged.
For secondary prevention, dual antiplatelet therapy (DAPT) remains the cornerstone following acute coronary syndrome (ACS).
Twelve months of aspirin combined with a potent P2Y12 inhibitor continues to be the standard approach, although shorter DAPT regimens followed by P2Y12 inhibitor monotherapy have emerged as effective strategies for reducing bleeding without compromising ischemic protection in appropriately selected patients.
The document also supports de-escalation from ticagrelor or prasugrel to clopidogrel after the first month in selected patients with increased bleeding risk.
The statement further highlights growing evidence supporting clopidogrel monotherapy beyond one year after ACS, suggesting that it may provide superior long-term ischemic protection with similar or even lower bleeding risk compared with aspirin alone.
In patients with stable coronary or peripheral artery disease who remain at high ischemic risk and have acceptable bleeding risk, the combination of low-dose rivaroxaban (2.5 mg twice daily) plus aspirin remains an important option for long-term secondary prevention.
Importantly, the ACC strongly advocates routine use of validated risk assessment tools—including DAPT, PRECISE-DAPT, and ARC-HBR—while emphasizing that these instruments should complement, rather than replace, individualized clinical judgment and shared decision-making.
The overarching message is clear: modern antiplatelet therapy is no longer defined by a fixed duration or universal regimen, but by precision medicine tailored to each patient’s evolving ischemic and bleeding profile.”
Title: Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology
Authors: Dharam J. Kumbhani, C. Michael Gibson, Scott Kinlay, Eric D. Peterson, Amy W. Pollak, Jacqueline E. Tamis-Holland, Freek W.A. Verheugt

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health